Socialiya - Entertainment. Knowledge. Community.
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2. S...

BUSINESS NEWS March 27, 2026

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2. Severe LAD-I is an ultra-rare, life-threatening pediatric...

33 views 0 likes 0 comments
Share:
First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2. Severe LAD-I is an ultra-rare, life-threatening pediatric...

Author: Business Wire

Read Original Article

Related News

Advertisement
socialiya
Advertisement
APNA POS
Advertisement

Top Categories

Advertisement
APNA POS
Advertisement
APNA POS
Advertisement
APNA POS
Advertisement
socialiya